Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma – a Swedish population-based study

References

• Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. Am J Hematol 2014;89:310–4.
   PubMed Web of Science ®Google Scholar
• Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973–2009. Blood 2012;4:990–6.
   Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;14:2373–80.
   Google Scholar
• A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;14:987–94.
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;4:235–42.
   Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good- prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 11:1013–22.
   Web of Science ®Google Scholar
• Eichenauer DA, Engert A. Advances in the treatment of Hodgkin lymphoma. Int J Hematol 2000;7:235–40.
   Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837–42.
   PubMed Web of Science ®Google Scholar
• Riihijarvi S, Taskinen M, Jerkeman M, Leppa S. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011;2:124–8.
   Google Scholar
• Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: A Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymph 2013;1:53–7.
   Google Scholar
• Szekely E, Hagberg O, Arnljots K, Jerkeman M. Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, IPI and extranodal presentation: A population based Swedish Lymphoma Registry study. Leuk Lymph 2014;55:1838–43.
   PubMed Web of Science ®Google Scholar
• Varga C, Holcroft C, Kezouh A, Bucatel S, Johnson N, Petrogiannis-Haliotis T, et al. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: A population based study. Leuk Lymph 2014;55:533–7.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;12:2040–5.
   Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;2:105–16.
   Web of Science ®Google Scholar
• Yakimchuk K, Jondal M, Okret S. Estrogen receptor alpha and beta in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol 2013;1–2:121–9.
   Google Scholar
• Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009; 2009:591753.
   PubMedGoogle Scholar
• Lu Y, Wang SS, Sullivan-Halley J, Chang ET, Clarke CA, Henderson KD, et al. Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer 2011;4:974–82.
   Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961; 6:101–21.
   PubMedGoogle Scholar
• Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006;3:272–8.
   Web of Science ®Google Scholar
• Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C. Reproducibility of self-reported menopause age at the 24-year follow-up of a population study of women in Goteborg, Sweden. Menopause 2005;3:275–80.
   Google Scholar
• Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: Clinical implications of extranodal versus nodal presentation – a population-based study of 1575 cases. Br J Haematol 2004;2:151–9.
   Google Scholar
• Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: A population-based analysis. Br J Haematol 2012;4:481–8.
   Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin 2013;1:11–30.
   Google Scholar
• Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005;4:411–23.
   Google Scholar
• Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 1998; 12:1271–6.
   Google Scholar
• Klein SL. The effects of hormones on sex differences in infection: From genes to behavior. Neurosci Biobehav Rev 2000;6:627–38.
   Google Scholar
• Drechsler S, Weixelbaumer K, Raeven P, Jafarmadar M, Khadem A, van Griensven M, et al. Relationship between age/gender-induced survival changes and the magnitude of inflammatory activation and organ dysfunction in post- traumatic sepsis. PLoS One 2012;12:e51457.
   Google Scholar
• Klein SL. Immune cells have sex and so should journal articles. Endocrinology 2012;6:2544–50.
   Google Scholar
• Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009;4:1174–82.
   Google Scholar
• Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;14:3276–84.
   Google Scholar
• Arnold AP, van Nas A, Lusis AJ. Systems biology asks new questions about sex differences. Trends Endocrinol Metab 2009;10:471–6.
   Google Scholar
• Vineis P, Wild CP. Global cancer patterns: Causes and prevention. Lancet 2014;383:549–57.
   PubMed Web of Science ®Google Scholar